Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders.

Bile acids are a family of steroid molecules generated in the liver by cholesterol oxidation. In addition to their role in nutrient absorption, bile acids are signaling molecules that exert genomic and non-genomic effects by activating TGR5 (M-BAR, GP-BAR1 or BG37) a G-protein-coupled receptor, and farnesoid X receptor (FXR), a member of the nuclear hormone receptor superfamily. Ligands for these receptors might be beneficial in treating disorders of lipid and glucose homeostasis. TGR5 ligands decrease blood glucose levels and increase energy expenditure by promoting intracellular thyroid hormone activation in thermogenically competent tissues. FXR agonists repress the synthesis of endogenous bile acids and reduce triglyceride, cholesterol and glucose plasma levels and are currently being tested in nonalcoholic steatohepatitis. FXR modulators are being developed to target selective gene clusters and avoid the negative impact of FXR on HDL biosynthesis. The development of dual FXR and TGR5 ligands could provide new opportunities for the treatment of lipid and glucose disorders.

[1]  W. Mckeehan,et al.  Independent Repression of Bile Acid Synthesis and Activation of c-Jun N-terminal Kinase (JNK) by Activated Hepatocyte Fibroblast Growth Factor Receptor 4 (FGFR4) and Bile Acids* , 2005, Journal of Biological Chemistry.

[2]  R. Savkur,et al.  Regulation of carbohydrate metabolism by the farnesoid X receptor. , 2005, Endocrinology.

[3]  Shawn P Williams,et al.  Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064. , 2008, Bioorganic & medicinal chemistry letters.

[4]  S. Kliewer,et al.  Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. , 2005, Cell metabolism.

[5]  B. Staels,et al.  Glucose regulates the expression of the farnesoid X receptor in liver. , 2004, Diabetes.

[6]  J. Auwerx,et al.  The small heterodimer partner interacts with the liver X receptor alpha and represses its transcriptional activity. , 2002, Molecular endocrinology.

[7]  J. W. Becker,et al.  Identification of a potent synthetic FXR agonist with an unexpected mode of binding and activation , 2008, Proceedings of the National Academy of Sciences.

[8]  J. Hardies,et al.  A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. , 2006, The New England journal of medicine.

[9]  Darrell R. Abernethy,et al.  International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels , 2003, Pharmacological Reviews.

[10]  G. Gwak,et al.  Bile acid-induced TGR5-dependent c-Jun-N terminal kinase activation leads to enhanced caspase 8 activation in hepatocytes. , 2007, Biochemical and biophysical research communications.

[11]  H. Davis,et al.  Targeted deletion of Gpbar1 protects mice from cholesterol gallstone formation. , 2006, The Biochemical journal.

[12]  S. Kliewer,et al.  Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine Published, JLR Papers in Press, August 24, 2007. , 2007, Journal of Lipid Research.

[13]  K. Houck,et al.  T0901317 is a dual LXR/FXR agonist. , 2004, Molecular genetics and metabolism.

[14]  Min-Bo Chen,et al.  3D-QSAR studies with the aid of molecular docking for a series of non-steroidal FXR agonists. , 2007, Bioorganic & medicinal chemistry letters.

[15]  B. Bouscarel,et al.  Bile acids and signal transduction: role in glucose homeostasis. , 2008, Cellular signalling.

[16]  Jasmine Chen,et al.  Identification of Gene-selective Modulators of the Bile Acid Receptor FXR* , 2003, The Journal of Biological Chemistry.

[17]  L. Moore,et al.  Identification of a chemical tool for the orphan nuclear receptor FXR. , 2000, Journal of medicinal chemistry.

[18]  Gabriele Costantino,et al.  Farnesoid X receptor: from structure to potential clinical applications. , 2005, Journal of medicinal chemistry.

[19]  D. Mangelsdorf,et al.  A Natural Product That Lowers Cholesterol As an Antagonist Ligand for FXR , 2002, Science.

[20]  J. Auwerx,et al.  Bile acids and the membrane bile acid receptor TGR5--connecting nutrition and metabolism. , 2008, Thyroid : official journal of the American Thyroid Association.

[21]  E. Distrutti,et al.  Antiatherosclerotic effect of farnesoid X receptor. , 2009, American journal of physiology. Heart and circulatory physiology.

[22]  Masataka Harada,et al.  A G Protein-coupled Receptor Responsive to Bile Acids* , 2003, The Journal of Biological Chemistry.

[23]  A. Fukamizu,et al.  Bile Acids Regulate Gluconeogenic Gene Expression via Small Heterodimer Partner-mediated Repression of Hepatocyte Nuclear Factor 4 and Foxo1* , 2004, Journal of Biological Chemistry.

[24]  P. Edwards,et al.  Peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α) regulates triglyceride metabolism by activation of the nuclear receptor FXR , 2004 .

[25]  Yanqiao Zhang,et al.  FXR, a multipurpose nuclear receptor. , 2006, Trends in biochemical sciences.

[26]  C. Liddle,et al.  Feed-forward Regulation of Bile Acid Detoxification by CYP3A4 , 2004, Journal of Biological Chemistry.

[27]  P. Edwards,et al.  FXR Deficiency Causes Reduced Atherosclerosis in Ldlr−/− Mice , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[28]  J. Auwerx,et al.  Nongenomic actions of bile acids. Synthesis and preliminary characterization of 23- and 6,23-alkyl-substituted bile acid derivatives as selective modulators for the G-protein coupled receptor TGR5. , 2007, Journal of medicinal chemistry.

[29]  B. Staels,et al.  Role of bile acids and bile acid receptors in metabolic regulation. , 2009, Physiological reviews.

[30]  Timothy M Willson,et al.  Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[31]  K. Houck,et al.  The Hypolipidemic Natural Product Guggulsterone Is a Promiscuous Steroid Receptor Ligand , 2005, Molecular Pharmacology.

[32]  S. Wright,et al.  Guggulsterone Is a Farnesoid X Receptor Antagonist in Coactivator Association Assays but Acts to Enhance Transcription of Bile Salt Export Pump* , 2003, The Journal of Biological Chemistry.

[33]  A. Tiwari,et al.  TGR5: an emerging bile acid G-protein-coupled receptor target for the potential treatment of metabolic disorders. , 2009, Drug discovery today.

[34]  G. Reaven.  Role of Insulin Resistance in Human Disease , 1988, Diabetes.

[35]  Takao Nakamura,et al.  Identification of membrane-type receptor for bile acids (M-BAR). , 2002, Biochemical and biophysical research communications.

[36]  Wen Xie,et al.  International Union of Pharmacology. LXII. The NR1H and NR1I Receptors: Constitutive Androstane Receptor, Pregnene X Receptor, Farnesoid X Receptor α, Farnesoid X Receptor β, Liver X Receptor α, Liver X Receptor β, and Vitamin D Receptor , 2006, Pharmacological Reviews.

[37]  H. Miyoshi,et al.  Targeted disruption of G protein-coupled bile acid receptor 1 (Gpbar1/M-Bar) in mice. , 2006, The Journal of endocrinology.

[38]  D. Häussinger,et al.  Expression and function of the bile acid receptor TGR5 in Kupffer cells. , 2008, Biochemical and biophysical research communications.

[39]  J. Auwerx,et al.  Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies. , 2008, Journal of medicinal chemistry.

[40]  Grace Guo,et al.  The Farnesoid X-receptor Is an Essential Regulator of Cholesterol Homeostasis* , 2003, The Journal of Biological Chemistry.

[41]  E. Distrutti,et al.  Targeting farnesoid X receptor for liver and metabolic disorders. , 2007, Trends in molecular medicine.

[42]  C. Huard,et al.  A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia. , 2009, American journal of physiology. Gastrointestinal and liver physiology.

[43]  S. Kliewer,et al.  FXR agonists and FGF15 reduce fecal bile acid excretion in a mouse model of bile acid malabsorption Published, JLR Papers in Press, September 6, 2007. , 2007, Journal of Lipid Research.

[44]  J. Chiang,et al.  Bile acids: regulation of synthesis , 2009, Journal of Lipid Research.

[45]  P. Dawson,et al.  OSTα‐OSTβ: A major basolateral bile acid and steroid transporter in human intestinal, renal, and biliary epithelia , 2005 .

[46]  J. Orava,et al.  Functional brown adipose tissue in healthy adults. , 2009, The New England journal of medicine.

[47]  D. Drucker,et al.  Biology of incretins: GLP-1 and GIP. , 2007, Gastroenterology.

[48]  G. Casari,et al.  Identification of Farnesoid X Receptor β as a Novel Mammalian Nuclear Receptor Sensing Lanosterol , 2003, Molecular and Cellular Biology.

[49]  C. J. Sinal,et al.  Loss of functional farnesoid X receptor increases atherosclerotic lesions in apolipoprotein E-deficient mice Published, JLR Papers in Press, September 26, 2005. DOI 10.1194/jlr.M500390-JLR200 , 2005, Journal of Lipid Research.

[50]  Roberto Pellicciari,et al.  Structural basis for bile acid binding and activation of the nuclear receptor FXR. , 2003, Molecular cell.

[51]  Antonio Macchiarulo,et al.  Molecular Field Analysis and 3D-Quantitative Structure-Activity Relationship Study (MFA 3D-QSAR) Unveil Novel Features of Bile Acid Recognition at TGR5 , 2008, J. Chem. Inf. Model..

[52]  D. Russell,et al.  Loss of nuclear receptor SHP impairs but does not eliminate negative feedback regulation of bile acid synthesis. , 2002, Developmental cell.

[53]  T. Willson,et al.  Farnesoid X-activated receptor induces apolipoprotein C-II transcription: a molecular mechanism linking plasma triglyceride levels to bile acids. , 2001, Molecular endocrinology.

[54]  J. Dallongeville,et al.  Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element. , 2002, The Journal of clinical investigation.

[55]  C. Lavie,et al.  Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. , 2009, Journal of the American College of Cardiology.

[56]  J. Auwerx,et al.  Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation , 2006, Nature.

[57]  Shufeng Zhou,et al.  Multidrug resistance associated proteins as determining factors of pharmacokinetics and pharmacodynamics of drugs. , 2007, Current drug metabolism.

[58]  T. A. Kerr,et al.  Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. , 2000, Molecular cell.

[59]  J. Auwerx,et al.  Anti-hyperglycemic activity of a TGR5 agonist isolated from Olea europaea. , 2007, Biochemical and biophysical research communications.

[60]  F. Lammert,et al.  Functional variants of the central bile acid sensor FXR identified in intrahepatic cholestasis of pregnancy. , 2007, Gastroenterology.

[61]  Kazuhide Inoue,et al.  The novel compounds that activate farnesoid X receptor: the diversity of their effects on gene expression. , 2008, Journal of pharmacological sciences.

[62]  M. Makishima,et al.  The orphan nuclear receptor, shp, mediates bile acid-induced inhibition of the rat bile acid transporter, ntcp. , 2001, Gastroenterology.

[63]  G. Tsujimoto,et al.  Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. , 2005, Biochemical and biophysical research communications.

[64]  Folkert Kuipers,et al.  The Farnesoid X Receptor Modulates Adiposity and Peripheral Insulin Sensitivity in Mice* , 2006, Journal of Biological Chemistry.

[65]  Wooin Lee,et al.  A common polymorphism in the bile acid receptor farnesoid X receptor is associated with decreased hepatic target gene expression. , 2007, Molecular endocrinology.

[66]  F. Baldelli,et al.  Farnesoid X receptor agonists in biliary tract disease , 2009, Current opinion in gastroenterology.

[67]  M. Evans,et al.  Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR−/− and apoE−/− mice Published, JLR Papers in Press, January 27, 2009. , 2009, Journal of Lipid Research.

[68]  M. Bowman,et al.  A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. , 2003, Molecular cell.

[69]  D. Russell.  The enzymes, regulation, and genetics of bile acid synthesis. , 2003, Annual review of biochemistry.

[70]  T. Osborne,et al.  FGF15/FGFR4 Integrates Growth Factor Signaling with Hepatic Bile Acid Metabolism and Insulin Action* , 2009, Journal of Biological Chemistry.

[71]  Masahiro Tohkin,et al.  Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis , 2000, Cell.

[72]  Sander M Houten,et al.  Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. , 2004, The Journal of clinical investigation.

[73]  G. Farrell,et al.  Nonalcoholic fatty liver disease: From steatosis to cirrhosis , 2006, Hepatology.

[74]  T. Willson,et al.  Protective Effects of 6-Ethyl Chenodeoxycholic Acid, a Farnesoid X Receptor Ligand, in Estrogen-Induced Cholestasis , 2005, Journal of Pharmacology and Experimental Therapeutics.

[75]  M. Trauner,et al.  Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations. , 2006, Molecular pharmaceutics.

[76]  L. Moore,et al.  A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. , 2000, Molecular cell.

[77]  D. Häussinger,et al.  The G‐protein coupled bile salt receptor TGR5 is expressed in liver sinusoidal endothelial cells , 2007, Hepatology.

[78]  Folkert Kuipers,et al.  The Farnesoid X Receptor Modulates Hepatic Carbohydrate Metabolism during the Fasting-Refeeding Transition* , 2005, Journal of Biological Chemistry.

[79]  Songwen Zhang,et al.  Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. , 2009, Journal of hepatology.

[80]  S. Ito,et al.  Activation of Nuclear Factor (Erythroid-2 Like) Factor 2 by Toxic Bile Acids Provokes Adaptive Defense Responses to Enhance Cell Survival at the Emergence of Oxidative Stress , 2007, Molecular Pharmacology.

[81]  T. Willson,et al.  6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. , 2002, Journal of medicinal chemistry.

[82]  Ke Ma,et al.  Farnesoid X receptor is essential for normal glucose homeostasis. , 2006, The Journal of clinical investigation.

[83]  Johan Auwerx,et al.  Targeting bile-acid signalling for metabolic diseases , 2008, Nature Reviews Drug Discovery.